title: Stalevo reduction in dyskinesia evaluation in Parkinson's disease results were expected from a pharmacokinetic viewpoint.
authors.forename: Dag
authors.initials: D
authors.lastname: Nyholm
authors.forename: Håkan
authors.initials: H
authors.lastname: Askmark
authors.forename: Sten-Magnus
authors.initials: SM
authors.lastname: Aquilonius
mesh_terms: D000978:Antiparkinson Agents / Q000009:adverse effects / Q000493:pharmacokinetics*; D002396:Catechols / Q000009:adverse effects / Q000493:pharmacokinetics*; D004409:Dyskinesia, Drug-Induced; D006801:Humans; D007980:Levodopa / Q000009:adverse effects / Q000493:pharmacokinetics*; D009570:Nitriles / Q000009:adverse effects / Q000493:pharmacokinetics*; D010300:Parkinson Disease / Q000188:drug therapy*
chemical_list: D000978:Antiparkinson Agents; D002396:Catechols; D009570:Nitriles; D007980:Levodopa; C071192:entacapone